Clinical trial · Interventional
The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation
NCT02737735CI-TRIAL-00021742unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the effect on decreasing chemotherapeutic toxicity and increasing anti-tumor treatment of Chinese Herbs based on syndrome differentiation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| standard chemotherapy medicine | Drug | — | UNRESOLVED |
| standard chemotherapy medicine combined with Chinese herbs | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Chemotherapy combined with compound herbal medicine
- description
- Standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks combined with compound Chinese herbal medicine for 2 years,which include 15 kinds of Chinese herbs:Thunberg fritillary bulb,antimutangenic ,cimicifuga foetida,astragalus,pinellia ,Radix Ophiopogonis ,Solanum nigrum,Hedyotis diffusa,Prunella vulgaris ,cordate houttuynia,Herba Patriniae,dried orange peel ,Codonopsis,Wolfiporia extensa,Coix seed,Rhizoma Alismatis.
- interventionNames
- Drug: standard chemotherapy medicine combined with Chinese herbs
- type
- ACTIVE_COMPARATOR
- label
- Chemotherapy
- description
- The therapy of standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks
- interventionNames
- Drug: standard chemotherapy medicine
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histology and cytology diagnosed IIIB or IV non-small-cell lung cancer (NSCLC) and untreated; Age \> 18 ages * Sex unlimited; ECOG (Eastern Cooperative Oncology Group) fitness score (Performance status, PS)≤2. * White blood cell count ≥ 3 x 10E9 / L, neutrophils ≥1 x 109 p/L, hemoglobin≥80 g/L , platelet ≥100 x 10E9 / L * ALT, AST, normal or less than 2 times, bilirubin is normal * Serum level in the normal range;Thr ecg is normal * Expected survival time≥ 3 months or more; * Agreed to the treatment combined traditional Chinese medicine with western medicine Exclusion Criteria: * Engaged in other clinical subjects * Pregnant or lactating women, women in childbearing age refuse contraceptives during the trail * Severe pneumonia, tuberculosis, lung abscess, myocarditis and other malignant tumor * Severe damage of heart, liver and kidney (cardiac function grade 3 \~ 4, ALT and/or AST 2 times more than normal , Cr more the normal limit) * Mental illness, Refused to partner; Cannot obtain informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.